Cereno Scientific AB: Cereno Scientific extends patent protection for drug candidate CS1 in the US and has filed to extend market exclusivity to 2045
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...
Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in March-April
Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage ...
ORYZON to Provide Corporate Progress Updates at Several Events in March-April
VanLanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon ...
ViiV Healthcare announces data from EMBRACE Phase IIb study
ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s ...
Le Lézard5d
IRLAB Publishes Preclinical Data on mesdopetam in the Esteemed European Journal of Neuroscience
GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB , a company discovering and developing novel ...
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
Data from a mid-stage study shows that treatment with Trevi's experimental drug reduced patients' 24-hour cough frequency by 57% over placebo.
Trevi’s Phase IIb chronic cough success spikes stock by 71%
The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.